NYSE:MANE 4 February 2026

Veradermics IPO Pops Above Range as Eli Lilly Lines Up a 5% Stake Play

Veradermics priced its upsized IPO at $17 per share, raising about $256.3 million ahead of its NYSE debut under the ticker “MANE” on Feb. 4. Eli Lilly disclosed plans to acquire up to 4.9% of post-IPO shares, though the move is not binding. Veradermics sold 15,077,647 new shares, valuing the company at roughly $596 million.

4 February 2026

Biotechnology·NYSE:MANE·Pharmaceutical Industry·Stock Market

Bombardier Class B Stock Surpasses 200-Day Moving Average on Strong Analyst Support
March 18, 2026, 4:11 AM EDT. Shares of Bombardier, Inc. Class B (TSE:BBD.B) climbed above its 200-day moving average of C$221.82, closing at C$253.80 on Tuesday with over 213,000 shares traded. Several analysts updated their outlooks recently. Scotiabank downgraded the rating to "sector perform" but raised the target price to C$295. Meanwhile, Raymond James, BMO Capital Markets, and Desjardins boosted their price targets up to C$305, maintaining "outperform" and "buy" ratings. The stock holds a consensus "Moderate Buy" from 10 analysts, with an average target price of C$256.50. Bombardier, with a market cap of C$25.12 billion and a P/E ratio of 28.36, continues to attract institutional interest amid its transportation equipment manufacturing business based in Canada.